Skip to main content
  • Contact Us
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
      • CDMO Intelligence
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Samsung

Evaluate

Thumbnail
April 13, 2022

Takeover-driven resurgence fails to materialise for biotech

Deal making in biosimilars dominates a slow start to the year for biopharma M&A.

Thumbnail
January 28, 2022

Biogen sells its Bioepis stake bit by bit

Article image
Vantage logo
July 09, 2020

Biopharma shares shake off the pandemic

Global drug stocks enthusiastically joined the recovery on the financial markets in the second quarter, more than offsetting earlier declines.

Article image
Vantage logo
June 05, 2018

Forecasts tell a tale of two continents for biosimilars

Despite government rhetoric, the US biosimilar market has failed to live up to expectations so far.

Vantage logo
October 31, 2017

Where is the growth for post-Humira Abbvie?

Vantage logo
September 28, 2017

Abbvie sets the date for cash cow slaughter

Vantage logo
August 25, 2017

Snippet roundup: Adamas and Alexion score approvals and Amgen gets the price right

Vantage logo
August 21, 2017

Vantage Point – Why generic competition might not stem price moderation calls

Vantage logo
July 25, 2017

Samsung leaps into its first US biosimilars battle

Vantage logo
July 21, 2017

Snippet roundup: a lingering Lingo and two more US green lights

Vantage logo
July 14, 2017

Roche’s biosimilar battle is just beginning

  • Load More

Latest Reports

July 27, 2023

H1 Round Up: The haves and the have-nots

July 21, 2023

ADA/EASL eBook

View more...

Editor's Picks

Vantage logo
July 03, 2023

Astrazeneca and Daiichi’s big reveal disappoints

Vantage logo
July 13, 2023

Pharma finds a way to gain weight

Vantage logo
July 03, 2023

Protagonist investors flake as psoriasis pill disappoints

Vantage logo
June 29, 2023

Approaching datasets for big pharma

Vantage logo
June 27, 2023

Nkarta goes back to basics

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up